{"filings":[{"id":99942,"accession_number":"0001193125-26-186939","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).","Pharma revenue $38.0M (+9% YoY); Diagnostics $72.2M, down from $102.8M due to Labcorp oncology asset sale.","Operating loss improved to $51.0M from $67.2M; cash $341.9M; $92M of stock repurchased under $200M authorization.","Phase 1 trials started for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma); in vivo CAR-T platform advancing.","FY2026 guidance reaffirmed: total revenue $530-560M; total costs $725-750M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":124196000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116250,"accession_number":"0001193125-26-116122","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health appoints former CFO Subbarao Uppaluri as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Subbarao V. Uppaluri, PhD, appointed to OPKO board effective March 18, 2026; term expires at 2026 annual meeting.","Uppaluri previously served as OPKO's SVP & CFO from 2007-2012 and consultant until 2014.","Appointment fills board vacancy created by passing of Dr. Richard Krasno, who served since 2017.","Board determined Uppaluri independent under SEC and Nasdaq rules; expected to join Compensation Committee.","Standard non-employee director compensation and indemnification agreement apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116249,"accession_number":"0001193125-26-076575","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.","Regeneron collaboration for multispecific antibodies: upfront + milestones >$200M per program, total >$1B.","Pharmaceuticals revenue $43.7M (+17% YoY); NGENLA profit share $12.5M, Rayaldee $8.8M.","Diagnostics revenue $71.1M (down 31% YoY) on asset sale; operating loss improved to $18.3M from $21.7M.","FY 2026 guidance: total revenue $530-560M; total costs $725-750M; R&D $125-135M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":606879000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132706,"accession_number":"0001193125-25-256325","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Q3 net income $21.6M; Regeneron collaboration with $1B+ potential; sells BioReference oncology to Labcorp for $225M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.","Entered multi-program Regeneron collaboration for multispecific antibodies; upfront plus milestones >$200M per program, total potential >$1B.","Completed sale of BioReference oncology assets to Labcorp for $225M ($192.5M cash + $32.5M earnout); net gain of $101.6M recorded.","Pharmaceuticals revenue $37.7M (Rayaldee $7.5M, up 29%); diagnostics revenue $95.2M, down due to prior-year asset sales.","Cash, cash equivalents and restricted cash $428.9M at Sep 30, 2025; $73.8M used in share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":458429000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149231,"accession_number":"0001193125-25-203530","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.","Assets include BioReference's oncology and oncology-related clinical testing services across the U.S.","OPKO to use portion of proceeds for share repurchase; continuing ops had ~$300M revenue in 2024.","CEO Phillip Frost says deal positions BioReference to focus on core testing and 4Kscore franchise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149230,"accession_number":"0000950170-25-100891","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.","Diagnostics revenue $101.1M (-22% YoY) on lower clinical test volume from BioReference asset sale; operating loss improved to $18.2M from $26.6M.","Pharmaceuticals revenue $40.7M (flat); operating loss $28.7M vs $24.8M, driven by higher R&D for pipeline programs.","Board authorized additional $100M share repurchase, total capacity $200M; $58.5M repurchased through June 30.","FDA approved 4Kscore Test without DRE; Merck Phase 1 EBV vaccine and multiple pipeline programs advancing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":306759000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168254,"accession_number":"0000950170-25-079098","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health grants stock options and bonuses to CEO Frost and other executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee granted stock options for 500,000 shares to CEO Phillip Frost, each at $1.31 exercise price.","CEO Frost receives $480,000 cash bonus; Vice Chairmen Hsiao and Zerhouni each get $450,000 bonuses and 500,000 options.","EVP Admin Steven Rubin: 437,500 options + $400,000 bonus; CFO Adam Logal: 437,500 options + $475,000 bonus.","Options vest ratably over four years and expire on the tenth anniversary of the grant date.","Total options granted to named officers: 2,375,000 shares; total bonuses: $2,255,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168253,"accession_number":"0001437749-25-013848","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health Q1 revenue down 14% to $149.9M; net loss narrows to $67.6M; signs $225M Labcorp asset sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $149.9M vs $173.7M YoY; net loss $0.10 per share vs $0.12 per share.","Signed definitive agreement to sell oncology testing assets to Labcorp for up to $225M ($192.5M at close + $32.5M earnout); expected close H2 2025.","Board authorized additional $100M for stock buyback (total $200M); ~$40.2M repurchased under prior program since July 2024.","Post-quarter: exchanged $159.2M convertible notes for 121.4M shares + $63.5M cash.","Collaboration with Entera Bio for oral GLP-1/glucagon tablet; OPKO purchased 3.7M Entera shares at $2.17/share."],"consensus_eps_estimate":-0.0693,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":149952000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168252,"accession_number":"0001437749-25-012806","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OPKO Health stockholders elect all 11 director nominees, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected; highest vote for Alice Lin-Tsing Yu (444.8M for).","Say-on-pay advisory vote passed with 439.3M for, 11.0M against.","Ratification of Ernst & Young as auditor for FY 2025 passed with 522.7M for.","Broker non-votes of ~76.2M on director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168251,"accession_number":"0001437749-25-010494","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"OPKO Health exchanges $159.2M convertible notes for 121.4M shares and $63.5M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $152.5M (Mar 27) plus $6.75M (Mar 28) of 3.75% Convertible Senior Notes due 2029.","Issued 121,437,998 common shares plus $63.5M cash (incl. accrued interest) in exchange.","Closing occurred April 1, 2025; all exchanged notes retired and no longer outstanding.","Shares issued without registration, relying on Section 4(a)(2) exemption.","Noteholders represented QIB or accredited investor status for the exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185439,"accession_number":"0001437749-25-009701","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"OPKO Health to exchange $152.5M convertible notes for 116.7M shares and ~$60.1M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchange of $152,471,000 principal of 3.75% Convertible Senior Notes due 2029 for 116,706,310 common shares and ~$60.1M cash, including accrued interest.","Closing scheduled April 1, 2025; Exchanged Notes will be retired.","Shares issued unregistered under Section 4(a)(2) based on Noteholder representations as QIBs or accredited investors.","Transaction reduces debt and interest expense but dilutes existing shareholders by adding 116.7M new shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185438,"accession_number":"0001437749-25-006898","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"OPKO Health to sell oncology testing assets to Labcorp for up to $225M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.","Divested assets generate ~$85-100M in annual revenue; deal expected to close H2 2025.","BioReference retains core NY/NJ clinical testing and 4Kscore franchise (~$300M 2024 revenue).","Labcorp expects acquisition to be accretive to earnings in year one.","Transaction includes customary closing conditions and state regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185437,"accession_number":"0001437749-25-005468","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health reports Q4 net income of $14M, revenue $183.6M; BARDA/Merck milestones boost pharma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated Q4 revenue $183.6M vs $181.9M; net income $14.0M ($0.01 diluted EPS) vs net loss of $66.5M in Q4 2023.","Pharma segment operating loss narrowed to $2.1M from $16.0M; IP transfer revenue rose to $43.1M (includes $12.5M Merck milestone, $23.8M BARDA).","Diagnostics revenue fell to $103.1M from $124.2M on asset sales; operating loss improved to $21.7M from $42.3M.","BARDA awarded additional $51M for COVID/influenza antibodies; total awards to ModeX now $110M, up to $205M if all options exercised.","Capital actions: repurchased $17M principal notes, 10.9M shares for $16.5M; reduced share count 10% in 2024; sold part of BioReference for $237.5M."],"consensus_eps_estimate":-0.0693,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":713142000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185436,"accession_number":"0001437749-25-001220","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OPKO Health management presents at J.P. Morgan Healthcare Conference; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management attended investor meetings at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.","Presentation materials furnished as Exhibit 99.1 are available on the company's website.","No specific financial results, guidance changes, or material corporate developments were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202028,"accession_number":"0001437749-24-033922","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.","Completed sale of select BioReference Health assets to Labcorp for $237.5M; continues oncology/urology nationwide.","Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share payments from Pfizer.","Board authorized $100M share repurchase program; repurchased 14.9M shares for $23.8M in Q3 and 8.7M more through Nov 6.","Awarded $51M additional BARDA funding ($26.9M COVID, $24.1M influenza) for ModeX multispecific antibodies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":529504000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218073,"accession_number":"0001437749-24-029310","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["1.02","2.01","7.01","9.01"],"status":"ready","headline":"OPKO Health closes $237.5M sale of BioReference clinical diagnostics assets to Labcorp","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Labcorp acquired select BioReference diagnostics assets outside NY/NJ for $237.5M cash.","Acquired assets generate ~$100M annual revenue; OPKO retains NY/NJ and oncology/urology ($400M).","BioReference repaid $9.7M credit facility with JPMorgan; no prepayment penalty.","Pro forma cash increases to ~$273M; estimated gain on sale ~$122.6M.","OPKO Chairman cites transaction as key step toward profitability and focus on core testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218072,"accession_number":"0001437749-24-025180","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.","NGENLA global launch ongoing; earned $6.3M gross profit share from Pfizer in Q2 (up from $3.8M).","Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share; retains milestone upside.","Board authorized $100M share repurchase program (~10.1% of shares outstanding).","Sale of BioReference laboratory assets to Labcorp for $237.5M expected close end of Q3 2024."],"consensus_eps_estimate":-0.1145,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":355872000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218071,"accession_number":"0001437749-24-023634","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OPKO Health grants 2.375M RSUs and bonuses to five named executive officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Phillip Frost: 500,000 RSUs + $480,000 bonus; other NEOs similar awards.","Total RSU grants: 2,375,000 shares; vest 50% on 2nd anniversary, then ratably.","CFO Adam Logal: 437,500 RSUs and $475,000 bonus.","Compensation Committee approved on July 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218070,"accession_number":"0001437749-24-022919","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"OPKO Health issues $250M senior secured notes due 2044, secured by NGENLA profit share payments from Pfizer","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Notes bear interest at 3-month SOFR + 7.5% (floor 4%); interest-only for first 4 years.","No principal payments required before July 2028; principal repaid from NGENLA profit share payments.","Proceeds provide non-dilutive capital for R&D, including multispecific antibody programs, and potential share/convertible note repurchases.","Exit fee of 3% on repayment; make-whole provision up to 200% of principal if prepaid after year 5.","OPKO retains full benefit of up to $100M in remaining milestone payments from Pfizer for NGENLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238020,"accession_number":"0001437749-24-015074","cik":944809,"company_name":"OPKO HEALTH, INC.","ticker":"OPK","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OPKO Health to sell BioReference assets to Labcorp for $237.5M; Q1 net loss $81.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Agreed to sell select BioReference Health assets to Labcorp for $237.5M; assets generate ~$100M annual revenue; closing expected H2 2024.","Q1 total revenue $173.7M (down 27% YoY); net loss $81.8M ($0.12/share) vs $18.3M loss a year ago.","Issued $230M 3.75% convertible notes due 2029; exchanged $144.4M of existing 4.50% notes; used $50M to repurchase common stock.","FDA cleared IND for MDX2001 tetraspecific antibody for solid tumors; Phase 1 trial enrollment expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":981619862.0155039,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}